| 70 |
60: Induction, Chitin degradation and resorption |
238: Induction, Pre-mature molting |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 16 |
17: Altered expression of AHR/ARNT pathway-dependent genes |
317: Altered, Cardiovascular development/function |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 17 |
17: Altered expression of AHR/ARNT pathway-dependent genes |
80: Up Regulation, CYP1A1 |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 18 |
18: Activation, AhR |
17: Altered expression of AHR/ARNT pathway-dependent genes |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 62 |
52: Decreased, Calcium influx |
341: Impairment, Learning and memory |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 51 |
39: Increased Cholinergic Signaling |
360: Decrease, Population growth rate |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 261 |
238: Induction, Pre-mature molting |
328: Decrease, Fecundity |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 287 |
261: Binding, SH-/selen-proteins |
158: N/A, Interferences with SH-/selen-proteins |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 296 |
366: Increased, Structural malformations |
342: Increased, Lethality |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 301 |
272: Activation/Proliferation, T-cells |
312: N/A, Allergic contact dermatitis on challenge |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 271 |
244: Alkylation, Protein |
209: Peptide Oxidation |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 303 |
276: Up Regulation, TGFbeta1 expression |
68: Increase, Collagen accumulation |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 304 |
276: Up Regulation, TGFbeta1 expression |
265: Increase, HSC activation |
Nov 29, 2016 |
Nov 29, 2016 |
None
|
| 263 |
238: Induction, Pre-mature molting |
351: Increased Mortality |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 262 |
238: Induction, Pre-mature molting |
350: Increase, Mortality |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 331 |
301: Binding, VEGF-A |
305: Inhibition, VegfR2 |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 236 |
209: Peptide Oxidation |
134: Increase, Kupffer cell activation |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 334 |
304: Decreased, VegfR2 |
305: Inhibition, VegfR2 |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 333 |
302: Production, VEGF-A |
304: Decreased, VegfR2 |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 332 |
302: Production, VEGF-A |
301: Binding, VEGF-A |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 330 |
301: Binding, VEGF-A |
304: Decreased, VegfR2 |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 253 |
219: Reduction, Plasma 17beta-estradiol concentrations |
309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development |
Nov 29, 2016 |
Nov 29, 2016 |
None
|
| 329 |
298: Insufficiency, Vascular |
183: Abnormal, Morphogenesis |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 368 |
352: N/A, Neurodegeneration |
386: Neuronal network function, Decreased |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 399 |
289: Decrease, Translocator protein (TSPO) |
413: Reduction, Testosterone synthesis in Leydig cells |
Nov 29, 2016 |
Dec 3, 2016 |
None
|